Background: Patient adherence to immunosuppressant regimens after organ transplant is crucial to preserve graft function, and simplifying the regimen improves adherence. In this study, our experience of conversion from twice-daily (b.i.d.) to once-daily (q.d.) tacrolimus (TAC) in stable liver transplant recipients is reviewed and the proper conversion regimen is investigated.
INTRODUCTION
Immune tolerance research to withdraw or minimize immunosuppressive drugs after solid organ transplantation is an active field. However, life-long intake of immunosuppressive drugs is essential to preserve graft function, and non-compliance remains a major problem after solid organ transplantation, leading to increased rejection episodes and graft loss (1, 2) .
Tacrolimus (TAC) is the major immunosuppressive drug in solid organ transplantation. Before the introduction of once-daily (q.d.) formulation, TAC was available as an im- to prevent allograft rejection. A prolonged-release formulation TAC administered q.d. in the morning provides more consistent exposure, improves patient adherence(3), and improves therapeutic efficacy, safety, and adherence in patients with solid organ transplants (3) (4) (5) (6) (7) (8) .
In this study, we review our experience of conversion from TAC b.i.d. to TAC q.d. formulation in stable liver transplant (LT) recipients, evaluate the safety and feasibility of conversion to TAC q.d. formulation, and examine the proper method of conversion, through level, liver function and kidney function. 
MATERIALS AND METHODS

From
RESULTS
Patient characteristics and conversion results are shown in Table 1 . Among 32 patients enrolled in this study, 24 patients were male and eight were female. The mean age at the time of conversion was 55 years (range; 18∼72) and mean time since LT was 56.8 months (range; 21∼94).
Immunosuppresive therapy at the time of conversion consisted of TAC alone in most patients (94%); TAC and mycophenolate mofetil in only two patients (6%). Liver cirrhosis caused by hepatitis B virus with or without hepatocellular carcinoma was the main indication of LT.
Biopsy-proven acute celluar rejection after LT occurred in Decreased TAC trough level after a 1:1 conversion in stable LT recipients was reported by several authors (3, (12) (13) (14) .
We also observed significantly decreased TAC trough levels after a 1:1 conversion and dose escalation was required to maintain TAC trough level in our study. Dopazo et al. (13) reported that TAC trough level decreased approximately 20% 1 month after conversion and reached initial value 6 to 12 months after conversion without dose adjustment in most patients (88%). However, dose adjustment was required to maintain proper TAC trough level in our study.
Sanko-Resmer et al. (14) included 112 stable LT recipients converted formulation with 1:1 ratio in whom the mean TAC trough level was reduced by 15% without any acute rejection, and remained stable (74.5% of the patients required no dose adjustment on conversion). In our study, 52% of the patients with stable liver function after conversion later required dose adjustment maintain TAC trough level and stable liver function. We suppose that these results were caused by the differences in immunosuppressant regimen and baseline TAC level. In our study, the TAC single regimen was adopted in most patients, and the baseline trough level was lower than in other studies due to minimization of TAC dose. Thus, dose adjustment was performed in more patients. 
